ML-007

{{Short description|Experimental muscarinic drug}} {{cs1 config|name-list-style=vanc|display-authors=6}} {{Infobox drug | drug_name = | image = | width = | caption =

<!-- Clinical data --> | pronounce = | tradename = | Drugs.com = | MedlinePlus = | licence_CA = | licence_EU = | DailyMedID = | licence_US = | pregnancy_AU = | pregnancy_category = | dependency_liability = | addiction_liability = | routes_of_administration = Oral<ref name="AdisInsight" /> | class = Muscarinic acetylcholine M₁ and M₄ receptor agonist<ref name="AdisInsight" /> | ATC_prefix = | ATC_suffix =

<!-- Legal status --> | legal_status =

<!-- Pharmacokinetic data --> | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action = | excretion =

<!-- Identifiers --> | CAS_number = | CAS_supplemental = | PubChem = | PubChemSubstance = | IUPHAR_ligand = | DrugBank = | ChemSpiderID = | UNII = | KEGG = | ChEBI = | ChEMBL = | NIAID_ChemDB = | PDB_ligand = | synonyms = ML007; ML-007/PAC; ML007/PAC

<!-- Chemical data --> | IUPAC_name = | C= | H= | N= | O= | SMILES = | StdInChI = | StdInChIKey = }}

'''ML-007''' is a selective muscarinic acetylcholine M₁ and M₄ receptor agonist which is under development for the treatment of schizophrenia, psychotic disorders, and dyskinesias.<ref name="AdisInsight">{{cite web | title=ML 007 | work = AdisInsight | publisher = Springer Nature Switzerland AG | date=9 January 2024 | url=https://adisinsight.springer.com/drugs/800062983 | access-date=21 October 2024}}</ref><ref name="Synapse">{{cite web | title=Delving into the Latest Updates on ML-007 with Synapse | website=Synapse | date=19 September 2024 | url=https://synapse.patsnap.com/drug/b28f987442e14a1b9abeed7005e6dbff | access-date=21 October 2024}}</ref><ref name="YohnHarveyBrannan2024">{{cite journal | vauthors = Yohn SE, Harvey PD, Brannan SK, Horan WP | title=The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia | journal=Frontiers in Psychiatry | publisher=Frontiers Media SA | volume=15 | date=4 October 2024 | issn=1664-0640 | doi=10.3389/fpsyt.2024.1421554 | doi-access=free | page=| pmid=39483736 | pmc=11525114 }}</ref><ref name="WalkerHuckstepBecker2024">{{cite journal | vauthors = Walker LC, Huckstep KL, Becker HC, Langmead CJ, Lawrence AJ | title = Targeting muscarinic receptors for the treatment of alcohol use disorders: Opportunities and hurdles for clinical development | journal = British Journal of Pharmacology | volume = 181 | issue = 22 | pages = 4385–4398 | date = November 2024 | pmid = 37005377 | doi = 10.1111/bph.16081 | doi-access = free }}</ref> It is being developed in combination with a peripherally selective muscarinic acetylcholine receptor antagonist (also known as ML-007/peripherally acting anticholinergic or ML-007/PAC).<ref name="WalkerHuckstepBecker2024" /><ref name="YohnHarveyBrannan2024" /> The drug is taken by mouth.<ref name="AdisInsight" />

As of January 2024, ML-007 is in phase 1 clinical trials for schizophrenia, psychotic disorders, and dyskinesias.<ref name="AdisInsight" /><ref name="Synapse" /><ref name="YohnHarveyBrannan2024" /> It is under development by MapLight Therapeutics.<ref name="AdisInsight" /><ref name="Synapse" /> The drug is a small molecule, but its chemical structure does not seem to have been disclosed.<ref name="WalkerHuckstepBecker2024" /><ref name="AdisInsight" /><ref name="Synapse" />

== See also == * Emraclidine * NBI-1117568 * NS-136 * Xanomeline/trospium

== References == {{Reflist}}

{{Muscarinic acetylcholine receptor modulators}}

Category:Combination drugs Category:Drugs with undisclosed chemical structures Category:Experimental drugs Category:Experimental drugs developed for schizophrenia Category:M1 receptor agonists Category:M4 receptor agonists

{{Nervous-system-drug-stub}}